Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid

Clinical Pharmacokinetics

Volumn 36, Issue 3, 1999, Pages 191-210

  Day, Richard O ^a,c   McLachlan, Andrew J ^b   Graham, Garry G ^a   Williams, Kenneth M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZAPROPAZONE; CARPROFEN; DICLOFENAC; ETODOLAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PARACETAMOL; PROTEIN; SALICYLIC ACID; TENOXICAM; TIAPROFENIC ACID; TOLMETIN;

BULLOUS SKIN DISEASE; COMPARTMENT MODEL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SYNOVIAL FLUID LEVEL; HUMAN; INFLAMMATION; ORAL DRUG ADMINISTRATION; PARTITION COEFFICIENT; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; TOPICAL DRUG ADMINISTRATION;

EID: 0032896464     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936030-00002     Document Type: Review

References (79)

1. Hadler NM. The biology of the extracellular space. Clin Rheum Dis 1981; 7: 71-97
2. Levick JR, McDonald JN. Fluid movement across synovium in healthy joints: role of synovial fluid macromolecules. Ann Rheum Dis 1995; 54: 417-23
3. Knight AD, Levick JR. The density and distribution of capillaries around a synovial cavity. Q J Exp Physiol 1983; 68: 629-44
4. Baciocco EA, Ilies RL. Ampicillin and kanamycin concentrations in joint fluid. Clin Pharmacol Ther 1971; 12: 858-63
5. Levick JR. Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum 1981; 24: 1550-60
6. Furst DE. Synovial fluid kinetics of non-steroidal anti-inflammatory drugs. Agents Actions Suppl 1985; 17: 65-78
7. Wallis WJ, Simkin PA, Nelp WB, et al. Intraarticular volume and clearance in human synovial effusions. Arthritis Rheum 1985; 28: 441-9
8. Wallis WJ, Simkin PA, Nelp WB. Protein traffic in human synovial effusions. Arthritis Rheum 1987; 30: 57-63
9. Myers SL, Brandt KD, Eilam O. Even low-grade synovitis significantly accelerates the clearance of protein from the canine knee. Arthritis Rheum 1995; 38: 1085-91
10. Simkin PA. Synovial permeability in rheumatoid arthritis. Arthritis Rheum 1979; 22: 689-96
11. Wallis WJ, Simkin PA, Nelp WB. Low synovial fluid clearance of iodide provides evidence of hypoperfusion in chronic rheumatoid arthritis. Arthritis Rheum 1985; 28: 1096-104
12. Hadler NM. Synovial fluids facilitate small solute diffusivity. Ann Rheum Dis 1980; 39: 580-5
13. Bauer W, Short CL, Bennett GA. The manner of removal of proteins from normal joints. J Exp Med 1932; 57: 419-33
14. Simkin PA, Benedict RS. Hydrostatic and oncotic determinants of microvascular fluid balance in normal canine joints. Arthritis Rheum 1990; 33: 80-6
15. O'Driscoll SW, Kumar A, Salter RB. The effect of the volume of effusion, joint position and continuous passive motion on intraarticular pressure in the rabbit knee. J Rheumatol 1983; 10: 360-3
16. Mapp PI, Grootveld MC, Blake DR. Hypoxia, oxidative stress and rheumatoid arthritis. Br Med Bull 1995; 51: 419-36
17. Richman AI, Su EY, Ho G. Reciprocal relationship of synovial fluid volume and oxygen tension. Arthritis Rheum 1981; 24: 701-5
18. Aarons L. The kinetics of flurbiprofen in synovial fluid. J Pharmacokinet Biopharm 1991; 19: 265-9
19. Aarons L. Sparse data analysis. Eur J Drug Metab Pharmacokinet 1993; 18: 97-100
20. Tod M, Pobel C, Le Gros V. et al. A population pharmacokinetic study of alminoprofen penetration into synovial fluid. Biopharm Drug Dispos 1995; 16: 627-34
21. Colburn WA. Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm 1981; 9: 367-88
22. Graham GG, Milligan MK, Day RO, et al. Therapeutic considerations from pharmacokinetics and metabolism: ibuprofen and paracetamol. In: Rainsford KD, Powanda MC, editors. Safety and efficacy of non-prescription (over-the-counter) analgesics and NSAIDs. Dordrecht: Kluwer Press, 1997: 77-92
23. Day RO, Williams KM, Graham GG, et al. Stereoselective disposition of ibuprofen enantiomers in synovial fluid. Clin Pharmacol Ther 1988; 43: 480-7
24. Seideman P, Lohrer F, Graham GG, et al. The stereoselective disposition of the enantiomers of ibuprofen in blood, blister and synovial fluid. Br J Clin Pharmacol 1994; 38: 221-7
25. Elmquist WF, Chan KKH, Sawchuck RJ. Transsynovial drug distribution: synovial mean transit time of diclofenac and other non-steroidal antiinflammatory drugs. Pharm Res 1994; 11: 1689-97
26. Simkin PA, Wu MP, Foster DM. Articular pharmacokinetics of protein-bound antirheumatic agents. Clin Pharmacokinet 1993; 25: 342-50
27. Rosenthal RK, Bayles TB, Fremont-Smith K. Simultaneous salicylate concentrations in synovial fluid and plasma in rheumatoid arthritis. Arthritis Rheum 1964; 7: 103-9
28. Wanwimolruk S, Brooks PM, Birkett DJ. Protein binding of non-steroidal anti-inflammatory drugs in plasma and synovial fluid of arthritic patients. Br J Clin Pharmacol 1983; 15: 91-4
29. Owen SG, Francis HW, Roberts MS. Disappearance kinetics of solutes from synovial fluid after intra-articular injection. Br J Clin Pharmacol 1994; 38: 349-55
30. Ahlström S, Gedda PO, Hedberg H. Disappearance of radioactive serum albumin from joints in rheumatoid arthritis. Acta Rheumatol Scand 1956; 2: 129-36
31. Neander G, Eriksson L-O, Wallin-Boll E, et al. Pharmacokinetics of intraarticular indomethacin in patients with osteoarthritis. Eur J Clin Pharmacol 1992; 42: 301-5
32. Wigginton SM, Chu BCF, Weisman MH, et al. Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. Arthritis Rheum 1980; 23: 119-22
33. Graham GG. Kinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Agents Actions Suppl 1988; 24: 66-75
34. Ray JE, Wade DN, Graham GG, et al. Pharmacokinetics or carprofen in plasma and synovial fluid. J Clin Pharmacol 1979; 19: 635-43
35. Mäkelä AL, Lempiäinen M, Ylijoki H. Ibuprofen levels in serum and synovial fluid. Stand J Rheumatol 1981; 39: 15-7
36. Emori HW, Champion GD, Bluestone R, et al. Simultaneous pharmacokinetics of indomelhacin in serum and synovial fluid. Ann Rheum Dis 1973; 32: 433-5
37. Netter P, Bannwarth B, Lapicque F, et al. Total and free ketoprofen in serum and synovial fluid after intramuscular injection. Clin Pharmacol Ther 1987; 42: 433-5
38. Day RO, Francis H, Vial J, et al. Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. J Rheumatol 1995; 22: 2295-303
39. Bertin P, Lapicque F, Payan E, et al. Sodium naproxen: concentration and effect on inflammatory response mediators in human synovial fluid. Eur J Clin Pharmacol 1994; 46: 3-7
40. Day RO, Williams KM, Graham S, et al. The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. Arthritis Rheum 1991; 34: 751-60
41. Bird HA, Allen JG, Dixon JS, et al. A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. Br J Rheumatol 1985; 24: 351-6
42. Lignière GC, Montagnani G, Alberici M, et al. Plasma and synovial fluid concentrations of piroxicam during prolonged treatment with piroxicam pivalic ester. Arzneimittel Forschung 1987; 37: 560-3
43. Kurowski M, Thabe H. The transsynovial distribution of oxaprozin. Agents Actions 1989; 27: 458-60
44. Fowler PD, Dawes PT. Osmosin: its effect on plasma and synovial fluid kinetics of indomethacin. Eur J Clin Pharmacol 1985; 27: 689-91
45. Rudy AC, Liu Y, Brater C, et al. Stereoselective pharmacokinetics and inversion of (R)-ketoprofen in healthy volunteers. J Clin Pharmacol 1998; 38 (2 Suppl.): 3S-10S
46. Brocks DR, Jamali F, Russell AS, et al. The stereoselective pharmacokinetics of etodolac in young and elderly subjects, and after cholecystectomy. J Clin Pharmacol 1992; 32: 982-9
47. Brocks DR, Jamali F, Russell AS. Stereoselective disposition of etodolac enantiomers in synovial fluid. J Clin Pharmacol 1991; 31: 741-6
48. Kraml M, Hicks DR, McKean M, et al. The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis. Clin Pharmacol Ther 1988; 43: 571-6
49. Chan KKH, Vyas KH, Brandt KD. In vitro protein binding of diclofenac sodium in plasma and synovial fluid. J Pharm Sci 1987; 76: 105-8
50. Evans AM, Nation RL, Sansom LN, et al. Stereoselective plasma protein binding of ibuprofen enantiomers. Eur J Clin Pharmacol 1989; 36: 283-90
51. Cummings NA, Nordby GL. Measurement of synovial fluid pH in normal and arthritic knees. Arthritis Rheum 1966; 9:47-55
52. Hinderling PH, Hartmann D, Crevoisier C, et al. Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio. Ther Drug Monit 1988; 10: 250-60
53. Hundal Ø, Kvien TK, Glennäs A, et al. Total and free plasma and total synovial fluid piroxicam concentrations: relationship to antiinflammatory effect in patients with reactive arthritis and other arthritides. Scand J Rheumatol 1993; 22: 183-7
54. Urquhart E. A comparison of synovial fluid concentrations of non-steroidal anti-inflammatory drugs with their in vitro activity. Agents Actions 1991; 32: 261-5
55. Kurowski M, Dunky A, Geddawi M. Effects of pirazolac on arachidonic metabolism in the human synovial system. Curr Med Res Opin 1987; 10: 494-501
56. Seppälä E, Nissilä M, Isomäki H, et al. Efects of non-steroidal anti-inflammatory drugs and prednisolone on synovial fluid white cells, prostaglandin E2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis. Scand J Rheumatol 1990; 19: 71-5
57. Caruso I, Moro E, Patrono C, et al. Plasma and synovial fluid pharmacokinetics and prostaglandin inhibitory effect of indoprofen in patients with rheumatoid arthritis. Scand J Rheumatol 1980; 9: 123-6
58. Tokunaga M, Ohuchi K, Yoshizawa S, et al. Change of prostaglandin E level in joint fluids after treatment with flurbiprofen in patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1981; 40: 462-5
59. Dromgoole SH, Furst DE, Desiraju RK, et al. Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis. Clin Pharmacol Ther 1982; 32: 371-7
60. Spahn H, Thabe K, Mutschler E, et al. Concentration of azapropazone in synovial tissues and fluid. Eur J Clin Pharmacol 1987; 32: 303-7
61. Jalava S, Saarimaa H, Anttila M, et al. Naproxen concentrations in serum, synovial fluid, and synovium. Scand J Rheumatol 1977; 6: 155-7
62. Bannwarth B, Lagrange F, Schaeverbeke T, et al. Naproxen concentrations in articular tissues after prolonged treatment with naproxen sodium in patients with arthritis of the hip. Eur J Clin Pharmacol 1998; 54: 811-3
63. Bannwarth B, Netter P, Lapicque F, et al. Tenoxicam concentrations in synovium and joint cartilage in humans. Agents Actions 1991; 32: 295-8
64. Lapicque F, Mainard D, Gillet P, et al. Stereoselective distribulion of tiaprofenic acid in synovium and cartilage in osteoarthritic patients. Eur J Clin Pharmacol 1996; 50 (4): 283-7
65. Kiistala U. Suction blister device for separation of viable epidermis from dermis. J Invest Dermatol 1968; 50: 129-37
66. Herfst MJ, Van Rees H. Suction blister fluid as a model for interstitial fluid in rats. Arch Dermatol Res 1978; 263: 325-34
67. Nowak A, Kadykow M, Klimowicz A. Penetration of trimethoprim and sulphamethoxazole into blister fluid. Eur J Clin Pharmacol 1983; 25: 825-7
68. Shyu WC, Quintialani R, Nightingale CH. An improved method to determine interstitial fluid pharmacokinetics. J Infect Dis 1985; 152: 1328-31
69. Oelkers R, Neupert W, Williams KM, et al. Disposition and effects of flurbiprofen enantiomers in human serum and blister fluid. Br J Clin Pharmacol 1997; 43: 145-53
70. Walker JS, Knihinicki RD, Seideman P, et al. Pharmacokinetics of ibuprofen enantiomers in plasma and suction blister fluid in healthy volunteers. J Pharm Sci 1993; 82: 787-90
71. Blaser J, Rieder HL, Luthy R. Interface-area-to-volume ratio of interstitial fluid in humans determined by pharmacokinetic analysis of netilmicin in small and large skin blisters. Antimicrob Agents Chemother 1991; 35: 837-9
72. Doherty NS, Anttila M, Dean PB. Penetration of naproxen and salicylate into inflammatory exudates in the rat. Ann Rheum Dis 1977; 36: 244-8
73. Martin SW, Stevens AJ, Brennan BS, et al. Regional drug delivery I: permeability characteristics of the rat 6-day-old air pouch model of inflammation. Pharm Res 1995; 12: 1980-6
74. Stevens AJ, Martin SW, Brennan BS, et al. Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. Pharm Res 1995; 12: 1987-96
75. Radermacher J, Jentsch D, Scholl MA, et al. Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol 1991; 31: 537-41
76. Dominkus M, Nicolakis M, Kotz R, et al. Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittel Forschung 1996; 46: 1138-43
77. Dawson M, McGee CM, Vine JH, et al. The disposition of biphenylacetic acid following topical administration. Eur J Clin Pharmacol 1988; 33: 539-42
78. Suh H, Jun HW, Dzimianski MT, et al. Pharmacokinetic and local tissue disposition studies of naproxen following topical administration in dogs and rats. Biopharm Drug Dispos 1997; 18: 623-33
79. Cross SE, Anderson C, Roberts MS. Topical penetration of commercial salicylate esters and salts using human isolated skin and clinical microdialysis studies. Br J Clin Pharmacol 1998; 46: 29-35